Next report date
Report period
Q4 2023
EPS estimate
—
Revenue estimate
—
−0.0181USD
−2.37 MUSD
1.02 MUSD
112.80 M
About Aequus Pharmaceuticals Inc.
Sector
CEO
Douglas Glen Janzen
Headquarters
Vancouver
Website
Employees (FY)
15
Founded
2013
FIGI
BBG008NVDGK6
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson, and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AQSZF is 0.0094 USD — it has decreased by 25.67% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Aequus Pharmaceuticals Inc. stocks are traded under the ticker AQSZF.
Aequus Pharmaceuticals Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
AQSZF stock is 34.54% volatile and has beta coefficient of 0.51. Check out the list of the most volatile stocks — is Aequus Pharmaceuticals Inc. there?
Yes, you can track Aequus Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
AQSZF net income for the last quarter is −591.57 K USD, while the quarter before that showed −528.74 K USD of net income which accounts for −11.88% change. Track more Aequus Pharmaceuticals Inc. financial stats to get the full picture.
Today Aequus Pharmaceuticals Inc. has the market capitalization of 1.46 M, it has decreased by 1.47% over the last week.
No, AQSZF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AQSZF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aequus Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 15.00 employees. See our rating of the largest employees — is Aequus Pharmaceuticals Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aequus Pharmaceuticals Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aequus Pharmaceuticals Inc. stock shows the sell signal. See more of Aequus Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aequus Pharmaceuticals Inc. EBITDA is −1.80 M USD, and current EBITDA margin is −171.64%. See more stats in Aequus Pharmaceuticals Inc. financial statements.